Valuation
- Market cap
- 885,974,000
- Revenue TTM
- $0
- Net income TTM
- $-39,870,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 142,000
- Avg volume
- 106,572
- Day's range
- $24.68 – $27.11
- Shares out
- 33,433,000
- Stochastic %K
- 11%
- Beta
- —
- Analysts
- Strong Sell
- Price target
- $44.00
Company profile
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP)...
Show more
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 949 284 6904
- Website
- https://www.spyglasspharma.com
- Address
- 15326 Alton Parkway, Irvine, United States
Latest news
No headlines yet.
